Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 9, 2013, Pages 1412-1421

  Lin, Ai Ling ^a   Zheng, Wei ^b   Halloran, Jonathan J ^a   Burbank, Raquel R ^a   Hussong, Stacy A ^a   Hart, Matthew J ^a,b   Javors, Martin ^b   Shih, Yen Yu Ian ^c   Muir, Eric ^a   Solano Fonseca, Rene ^a   Strong, Randy ^a,b,d   Richardson, Arlan G ^a,b,d   Lechleiter, James D ^b   Fox, Peter T ^a   Galvan, Veronica ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

age associated; Alzheimer?s disease; cerebral amyloid angiopathy; nitric oxide synthase; rapamycin; target of rapamycin (TOR); vascular dysfunction

Indexed keywords

ACETYLCHOLINE; AMYLOID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN BLOOD VESSEL INTEGRITY; BRAIN HEMORRHAGE; BRAIN METABOLISM; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; LIFESPAN; MALE; MEMORY; METABOLIC RATE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; VASODILATATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-BACTERIAL AGENTS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MEMORY; MICE; MICE, TRANSGENIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITROARGININE; PHOSPHORYLATION; SIROLIMUS; VASODILATION;

EID: 84883740640     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.82     Document Type: Article

References (68)

1. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000; 903: 457-465. (Pubitemid 30251589)
2. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360. (Pubitemid 38568496)
3. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci 2003; 23: 7889-7896. (Pubitemid 37052357)
4. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol 2007; 62: 59-66. (Pubitemid 47235281)
5. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-817. (Pubitemid 27111317)
6. Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST et al. Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol advance online publication, 29 January 2013; doi:10.1002/ana.23845 (e-pub ahead of print); PMID: 23495089.
7. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001; 7: 612-618. (Pubitemid 32448330)
8. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000; 47: 739-747. (Pubitemid 30390194)
9. Tong XK, Nicolakakis N, Kocharyan A, Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci 2005; 25: 11165-11174. (Pubitemid 43089561)
10. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging 2009; 30: 1936-1948.
11. Marin J, Rodriguez-Martinez MA. Age-related changes in vascular responses. Exp Gerontol 1999; 34: 503-512. (Pubitemid 29383869)
12. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738.
13. Prisby RD, Dominguez 2nd JM, Muller-Delp J, Allen MR, Delp MD. Aging and estrogen status: a possible endothelium-dependent vascular coupling mechanism in bone remodeling. PLoS One 2012; 7: e48564.
14. Cantin S, Villien M, Moreaud O, Tropres I, Keignart S, Chipon E et al. Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI. Neuroimage 2011; 58: 579-587.
15. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009; 11: 143-153.
16. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005; 11: 959-965. (Pubitemid 41294441)
17. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17: 596-603. (Pubitemid 41540408)
18. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395.
19. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE et al. Rapamycin slows aging in mice. Aging Cell 2012; 11: 675-682.
20. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66: 191-201.
21. Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, Benjamin LE et al. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal 2009; 2: ra11.
22. Yepuri G, Velagapudi S, Xiong Y, Rajapakse AG, Montani JP, Ming XF et al. Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging. Aging Cell 2012; 11: 1005-1016.
23. Chauhan A, Sharma U, Jagannathan NR, Reeta KH, Gupta YK. Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats. Behav Brain Res 2011; 225: 603-609.
24. Zhang W, Khatibi NH, Yamaguchi-Okada M, Yan J, Chen C, Hu Q et al. Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines. Exp Neurol 2012; 233: 799-806.
25. Parlar A, Can C, Erol A, Ulker S. Posttransplantation therapeutic rapamycin concentration protects nitric oxide-related vascular endothelial function: comparative effects in rat thoracic aorta and coronary endothelial cell culture. Transplant Proc 2010; 42: 1923-1930.
26. Corbin F, Blaise GA, Parent M, Chen H, Daloze PM. Effect of rapamycin on rat aortic ring vasomotion. J Cardiovascul Pharmacol 1994; 24: 813-817. (Pubitemid 24334576)
27. Horigome M, Kumazaki S, Hattori N, Kasai H, Horigome M, Aizawa K et al. Noninvasive evaluation of coronary endothelial function following sirolimuseluting stent implantation by using positron emission tomography. Cardiology 2009; 114: 157-163.
28. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236. (Pubitemid 40966848)
29. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-2111.
30. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J 2012; 33: 1325-1333.
31. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010; 285: 13107-13120.
32. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloidbeta levels in a mouse model of Alzheimer's disease. PLoS One 2010; 5: e9979.
33. Pierce A, Podlutskaya N, Halloran JJ, Hussong SA, Lin PY, Burbank R et al. Overexpression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease. J Neurochem 2012; 124: 880-893.
34. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 2012; 11: 326-335.
35. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 2006; 103: 7130-7135.
36. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999; 96: 3228-3233. (Pubitemid 29148873)
37. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20: 4050-4058. (Pubitemid 30365675)
38. Lee WC, Chang CH, Ho CL, Chen LC, Wu YH, Chen JT et al. Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model. J Biomed Biotechnol 2011; 2011: 535902.
39. Duong TQ, Silva AC, Lee SP, Kim SG. Functional MRI of calcium-dependent synaptic activity: cross correlation with CBF and BOLD measurements. Magn Reson Med 2000; 43: 383-392. (Pubitemid 30127525)
40. Muir ER, Shen Q, Duong TQ. Cerebral blood flow MRI in mice using the cardiacspin-labeling technique. Magn Reson Med 2008; 60: 744-748.
41. Zheng W, Watts LT, Holstein DM, Prajapati SI, Keller C, Grass EH et al. Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria. PLoS One 2010; 5: e14401.
42. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60. (Pubitemid 14088970)
43. Zhang J, Gorostiza OF, Tang H, Bredesen DE, Galvan V. Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience. Behav Brain Res 2010; 206: 202-207.
44. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS biology 2010; 8: e1000412.
45. Galvan V, Zhang J, Gorostiza OF, Banwait S, Huang W, Ataie M et al. Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664. Behav Brain Res 2008; 191: 246-255.
46. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754. (Pubitemid 46717684)
47. Venero C, Tilling T, Hermans-Borgmeyer I, Herrero AI, Schachner M, Sandi C. Water maze learning and forebrain mRNA expression of the neural cell adhesion molecule L1. J Neurosci Res 2004; 75: 172-181. (Pubitemid 38049388)
48. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118: 103-113.
49. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3: 184-190. (Pubitemid 38232669)
50. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006; 26: 1343-1354. (Pubitemid 43237005)
51. Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imag Biol 2009; 11: 236-240.
52. Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998; 51: 690-694. (Pubitemid 28449244)
53. Champion HC, Kadowitz PJ. Vasodilator responses to acetylcholine, bradykinin, and substance P are mediated by a TEA-sensitive mechanism. Am J Physiol 1997; 273(1 Pt 2): R414-R422.
54. Schleicher M, Yu J, Murata T, Derakhshan B, Atochin D, Qian L et al. The Akt1-eNOS axis illustrates the specificity of kinase-substrate relationships in vivo. Sci Signal 2009; 2: ra41.
55. Gewirtz H. Letter regarding article by Kaufmann et al. 'systemic inhibition of nitric oxide synthase unmasks neural constraint of maximal myocardial blood flow in humans'. Circulation 2005; 111: e278-e279author reply e278-9.
56. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379. (Pubitemid 35346131)
57. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25: 629-636.
58. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1: 24.
59. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010; 24: 198-203.
60. Sperling RA, Jack Jr CR, Black SE, Frosch MP, Greenberg SM, Hyman BT et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer's Dement 2011; 7: 367-385.
61. Atwood CS, Bishop GM, Perry G, Smith MA. Amyloid-beta: a vascular sealant that protects against hemorrhage? J Neurosci Res 2002; 70: 356. (Pubitemid 35222372)
62. Poisnel G, Herard AS, El Tannir El Tayara N, Bourrin E, Volk A, Kober F et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging 2012; 33: 1995-2005.
63. Cheng C, Tempel D, Oostlander A, Helderman F, Gijsen F, Wentzel J et al. Rapamycin modulates the eNOS vs shear stress relationship. Cardiovasc Res 2008; 78: 123-129. (Pubitemid 351430952)
64. Naoum JJ, Zhang S, Woodside KJ, Song W, Guo Q, Belalcazar LM et al. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. Surgery 2004; 136: 323-328. (Pubitemid 39037672)
65. Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R et al. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest 2007; 117: 1961-1967. (Pubitemid 47036330)
66. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058. (Pubitemid 41161231)
67. Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005; 146: 1328-1337. (Pubitemid 40289320)
68. Shaw RJ, Ras Cantley LC. PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430. (Pubitemid 44050136)